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Abstract
Background: Colorectal cancer (CRC) is the third most prevalent type of cancer in the world.
Its prognosis is closely related to the disease stage at the time of diagnosis. Early detection of
symptomless CRC or precursor lesions through population screening could reduce CRC mortality.
However, screening programs are only effective if enough people are willing to participate. This
study aims to asses the uptake of a second round of fecal occult blood test (FOBt) based screening
and to explore factors that could potentially increase this uptake.
Methods and design: Two years after the first screening round, 10.000 average risk persons,
aged 50 to 75, will again receive an invitation to participate in immunohistochemical FOBt (iFOBt)
based screening. Eligible persons will be recruited through a city population database. Invitees will
be randomized to receive either an iFOBt with a faeces collection paper or an iFOBt without a
collection paper. The iFOBts will be analyzed in a specialized laboratory at the Academic Medical
Centre. Positive iFOBts will be followed by a consultation at our outpatient clinic and, in the
absence of contra-indications and after informed consent, by a colonoscopy. The primary outcome
measure is the participation rate. Secondary outcome measures are the effect of the addition of a
collection paper on the participation rate, reasons for participation and non-participation,
measures of informed choice and psychological consequences of screening and measures of
psychological and physical burden associated with the iFOBt and the colonoscopy. Another
secondary outcome measure is the diagnostic yield of the program.
Discussion: In order to implement population screening for colorectal cancer in the Netherlands,
information is needed on the uptake of repeated rounds of FOBt-based screening and on factors
that could potentially increase this uptake in the future since effectiveness of such a program
depends on the willingness of persons to participate. This study will provide information on the
actual uptake and perception of a second round of iFOBt-based screening. The results of this study
will contribute to the future implementation of a national colorectal screening program in the
Netherlands.
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Colorectal cancer (CRC) is the third most prevalent type
of cancer in the world. Each year more than 940.000 per-
sons are diagnosed with CRC and 500.000 persons die
from the disease [1]. In the Netherlands, CRC accounted
for over 4700 deaths in 2007[2,3]. The prognosis of
patients with CRC is closely related to the disease stage at
the time of the diagnosis. Five-year survival is 90% in
localized disease but only 68% for disease with lymph
node involvement. If distant metastases are present, sur-
vival drops to 10%[4]. Many patients are diagnosed in an
advanced stage, thus resulting in poor survival. Early
detection of symptomless CRC or its precursor lesions by
population screening could reduce CRC mortality since
removal of these precursors during colonoscopy reduces
the incidence of CRC[5].
There are several options for CRC screening falling into
two broad categories: stool tests and structural exams.
Stool tests include fecal occult blood tests (FOBt) and tests
for exfoliated DNA. Structural exams include flexible sig-
moidoscopy, total colonoscopy and computed tomo-
graphic colonography (CTC). FOBt is the only screening
method with a documented CRC mortality reduction in
randomized controlled trials. The efficacy of strategies
based on repeated guaiac FOBt has been established in
three randomized trials and one non-randomized con-
trolled trial [6-9]. A meta-analysis after several rounds of
these continuing trials showed a CRC mortality reduction
of 14% during a 10-year screening period[10].
The United Kingdom, France, Finland and Australia pro-
vide nationally organized bowel cancer screening pro-
grams. Several other countries, including Germany, the
United States and Italy, recommend CRC screening but do
not offer screening as part of an organized national pro-
gram. In the past few years, several project-groups have
started to study the feasibility, acceptance and cost-effec-
tiveness of a national colorectal cancer screening program
in the Netherlands. In 2006 our research group, in collab-
oration with the Radboud Hospital in Nijmegen, started a
study on the implementation of invitation based popula-
tion screening with FOBt in two regions of the Nether-
lands. In this pilot study, 20.000 asymptomatic
individuals, aged 50–75, were invited to take part in one
round of FOB testing and they were randomized to either
a guaiac-based (gFOBt) or immunochemical FOBt
(iFOBt). Invitation of participants was from May 2006
until January 2007. Primary goals of this implementation
study were to determine the participation rate, feasibility
and logistics of this type of screening. In this study, an
overall participation rate of 53% was observed. Participa-
tion rate in the iFOBt group was significantly higher than
in the gFOBt group (60% vs 47%)[11]. Also, detection
rates for advanced adenomas and cancer were higher for
iFOBt although also more colonoscopies had to be per-
formed.
Since the effectiveness of a FOBt-based screening program
in reducing mortality from CRC is highly dependent on
participants' willingness to repeat testing at regular inter-
vals, there is a need for information on adherence to con-
secutive rounds of FOBt screening. Information on actual
uptake is needed before well-informed decisions on
nationwide introduction of a CRC screening programme
in the Netherlands can be made.
To obtain information on participants' willingness to take
part in repeated rounds of FOBt-based screening we
decided to add a second screening round to the pilot study
described above. In the present study the same cohort of
the Amsterdam region that was studied in the first screen-
ing round will be again invited for FOBt-based screening
after an interval of two years. Only the iFOBt will be used
in this second round since it was associated with a higher
participation rate in our first round and it had higher CRC
detection rates. By focusing on the exact same group of
persons we intend to represent the real life situation once
a nationwide program is in place.
Participation rate will be the major focus of the present
study but we will also try to identify factors that are asso-
ciated with participation and non-participation. Particu-
larly, we want to explore whether the addition of a
collection paper makes people more willing to participate.
It is hypothesized that the handling of faeces is a barrier to
participation. Facilitating the collection process by adding
a collection paper could potentially lower this barrier and
increase participation.
Besides pursuing a high participation rate, it is also impor-
tant that invitees are enabled to make a well-informed
decision on participation. In order to make an informed
decision invitees need to have sufficient insight into the
pros and cons of taking part in the program. This study
will therefore also evaluate to what extent invitees' deci-
sions to participate or not are made in a well-informed
fashion. Furthermore, the psychological and physical
impact of taking part in the screening program and possi-
ble follow-up investigations will be evaluated. Insight into
the impact of participation is important because negative
experiences can act as a barrier for future participation.
Finally, the diagnostic yield of this second round of
screening will be evaluated and compared to the first
round. It is hypothesized that the majority of advanced
lesions were already detected during the first round.
Therefore we expect to find a smaller number of patients
with advanced lesions compared to the first round.Page 2 of 7
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Objectives
Primary objective
To evaluate the participation rate in a second round of
iFOBt-based colorectal cancer screening in the Nether-
lands, two years after the first round.
Secondary objectives
• To evaluate the effect of the addition of a faeces collec-
tion paper to the iFOBt-kit on the participation rate;
• To compare participation rates between the first and sec-
ond round;
• To compare the participation rates in groups that were
defined as participants or non-participants in the first
round;
• To evaluate the diagnostic yield (detection rates of can-
cer, high-risk adenoma and low-risk adenoma) and com-
plication rate of iFOBt and colonoscopy and to compare
these to results of the first screening round;
• To compare the baseline characteristics of participants
and non-participants;
• To evaluate factors influencing the decision to partici-
pate;
• To evaluate invitees' ability to make a well-informed
decision to participate;
• To evaluate participants' experience with the screening
program in terms of their perception and the burden of
the iFOBt;
• To evaluate the psychological impact on participants of
receiving a positive test result;
• To evaluate the burden of the colonoscopy in iFOBt pos-
itives;
Study design and randomization
The study design is a cohort study examining the partici-
pation rate of a second round of FOBt screening. Within
the cohort study a randomized controlled trial will be exe-
cuted comparing the use of a collection paper versus no
collection paper on the participation rate. All persons eli-
gible for invitation are pre-randomized to one of both
groups before informed-consent is obtained. Through
randomization, non-responders to the previous round,
responders to the previous round and first-time invitees
will be equally distributed over both study groups.
Study population
Our study population consists of 10.000 average risk per-
sons between 50 and 75 years of age with the postal code
of our target area. The target area of the second round is
identical to the target area of the first round and is selected
because it had an average uptake in the nationwide breast
cancer screening program. Thus, among the invitees of the
second round 3 different groups can be identified: 1) non-
responders to the first round; 2) responders to the first
round; 3) first-time invitees (persons aged 50–75 that
moved into the target area or persons that turned 50
within the last 2 years).
Institutionalized people will be excluded from participa-
tion. Responders to the first round that tested positive in
the first round and had a follow-up colonoscopy will not
be re-invited. They will be advised follow-up conform the
national guidelines on surveillance colonoscopy[12].
Other exclusion criteria are CRC symptoms in the last
three months (rectal blood loss and/or changed bowel
habits and/or unintentional weight loss). These sympto-
matic persons will be advised to contact their general phy-
sician and not to participate in the study. Also, persons
with a life-expectancy of less than 5 years and persons that
have undergone a colonoscopy in the previous 2 years will
be excluded from participation.
Invitation procedure
Invitation will take place from August 2008 until June
2009. The screening program uses a centralized invitation
procedure and all invitations will be sent out by the
regional Comprehensive Cancer Centre Amsterdam. This
institution is also involved in the organization of other
population-based cancer screening programmes in the
region including breast and cervical cancer screening. All
persons will receive an invitation kit by postal mail con-
taining an invitation letter, an information leaflet, an
immunochemical FOBt, a test instruction and a fre-
quently asked questions card. A collection paper to facili-
tate the collection of faeces will be enclosed in half of the
invitation kits.
A reminder will be sent after two and eight weeks.
Information leaflet
The information leaflet is an updated version of the leaflet
that was used in the first round. The main difference is
that it is adjusted following the principle of informed
choice. This principle states that in order to enable a per-
son to make a well-informed decision to participate in a
screening program or not, certain information has to be
available to this person. The information that was alreadyPage 3 of 7
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information relevant to colorectal screening: details of
CRC, details of the iFOBt, possibility of false-negative and
false-positive results, details of the follow-up investiga-
tion colonoscopy, prognosis and treatment options, and
details of benefits and harms. Also, the freedom of choice
to participate in the program or not is emphasized.
iFOBt
The iFOBt that will be used in this study is the OC-sensor
(Eiken Chemical Co, Tokyo, Japan). This is the same
iFOBt that was used in the first round. This is a clinical
laboratory-based, automated, immunochemical test that
measures human haemoglobin content of a stool sample.
No diet restrictions are necessary before performing the
test.
The iFOBt consists of a sampling bottle with a sampling
probe attached to the cap. Participants are instructed to
collect the faeces sample by scraping the probe over a
broad area of the stool surface. After the sample is taken,
the probe is reinserted into the sampling bottle. By rein-
serting the probe, the fecal sample is suspended in haemo-
globin-stabilizing buffer. Participants are instructed to
keep the bottle in a dark and cool place and to return it as
soon as possible.
Returned iFOBts will be collected at the specialized labo-
ratory of the AMC and will be processed by quantitative
haemoglobin analysis by the OC-MICRO automated
instrument using a 50 ng Hb/mL threshold to determine
positivity.
Collection paper
All persons randomized to the collection paper group will
receive a floating collection paper (Eiken Chemical Co,
Tokyo, Japan) with their iFOBt. This is a biodegradable
disposable paper float that has to be placed in the toilet
bowl to immobilize the stool for easy sampling.
Informed consent
Written informed consent will be obtained from all partic-
ipants before analyzing the stool sample. Enclosed in the
invitation kit is an informed consent form that partici-
pants are asked to return together with the test bottle. Test
bottles will not be processed in the absence of a signed
informed consent. When the informed consent is lacking,
a notification will be sent to the participant together with
a request to return the informed consent form.
Provision of test results
All specimens will be analyzed in a specialized laboratory.
Participants will receive the test result by postal mail. A
positive test result is defined as an Hb content of 50 ng/
mL or more. In this case the participant will be invited for
a consultation at the colorectal screening centre in the
AMC to discuss the recommended follow-up investiga-
tion: the colonoscopy. In case of a negative test result no
follow-up is needed. In case of a positive test result, the
general practitioner will also be informed.
Follow-up colonoscopy
During the consultation at the colorectal screening centre,
information is given on the consequences of the positive
test result. In absence of any contraindications a colonos-
copy will be advised and all relevant information on this
examination (technique, risks and alternatives) will be
given. If the participant consents, a colonoscopy will be
performed within two weeks after the consultation.
Colonoscopy is considered the clinical reference standard
for detection of adenomatous polyps and CRC. The pro-
cedure will be performed in our screening centre accord-
ing to quality guidelines, adapted from the recently
published guidelines of the American Society for Gas-
trointestinal Endoscopy[13]. In case of polyps or cancer,
endoscopic removal of the lesion will be attempted dur-
ing the same procedure. If immediate endoscopic treat-
ment is impossible, biopsies will be obtained and
pathological assessment of these tissue samples will pro-
vide definitive diagnosis so further treatment can be initi-
ated.
Lesions
Of all lesions, data on location (centimetres from anus,
segment of the colon), size (millimetres) macroscopic
aspect (hyperplastic, adenomatous, carcinomatous), mor-
phology (sessile, pedunculated, flat, depressed), diagnos-
tic or therapeutic procedure (total polypectomy,
piecemeal polypectomy, biopsy), use of saline and/or
epinephrine), and macroscopic involvement of margins
will be recorded during the colonoscopy.
Pathology
One experienced gastrointestinal pathologist will evaluate
all samples. Of each lesion the histology (hyperplastic
polyp, serrated adenoma, tubular adenoma, tubulovillous
adenoma, villous adenoma or carcinoma,) and grade of
dysplasia (low- or high-grade) will be assessed according
to the Vienna classification.
Follow-up after colonoscopy
The findings at colonoscopy will be discussed two weeks
after the colonoscopy through a consultation by tele-
phone or at the outpatient clinic. A confirmation of the
colonoscopy result will be sent by postal mail. In case of a
negative colonoscopy, no follow-up is needed. Follow-up
of patients after removal of adenomatous polyps or cancerPage 4 of 7
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ing to the Dutch CBO consensus[12]. Cases of CRC will
be referred for appropriate management (e.g. consulta-
tion of a surgeon). The general practitioner will also
receive a report of the colonoscopy procedure.
Questionnaires
Socioeconomic and demographic characteristics
Baseline characteristics as age, marital status, education,
employment and ethnicity will be recorded by a question-
naire two weeks after the invitation is sent.
Informed choice
Informed choice (knowledge and attitude) will be meas-
ured at baseline.
To evaluate whether the principle of informed choice
applies, it is necessary to understand the knowledge, atti-
tude and behaviour of the invited persons. The decision to
participate in screening will be classified as an informed
choice if: a) the participant has a positive attitude towards
undergoing a test; b) the participant has relevant knowl-
edge about the test. Knowledge is considered relevant if it
covers 12 general domains. (These domains are applicable
to all types of mass screening and are adapted from the
Dutch prenatal screening for Down syndrome[14]) and c)
this person actually undergoes the test. The decision not
to participate in screening will be classified as an informed
choice if: a) an individual has a negative attitude towards
undergoing a test; b) an individual has relevant knowl-
edge about the test; and c) this person does not undergo
the test. All choices that occur when individuals do not
have relevant knowledge or when their attitudes are not
reflected in their behaviour are to be considered unin-
formed[15].
Knowledge about screening with iFOBt will be measured
using 24 statements derived from expert opinion and
information obtained in the first screening round, with
two response options (e.g. "the fecal occult blood test has
to be repeated every 2 years" [correct-incorrect]). The
number of correct items is used as the knowledge score.
Attitude regarding undergoing screening will be measured
by 4 items, each scored on a 7-point scale (e.g. "for me,
having the screening test for colorectal cancer would
be...." [a good idea-a bad idea]. Attitude items are based
on the Marteau's measure of informed choice[15]. Screen-
ing behaviour is measured by either participation or non-
participation in the present study (i.e. returning of the
iFOBt).
Reasons for (non)participation
Reasons for (non)participation will be collected in all
invitees at baseline.
For the present study the Health Belief Model (HBM)[16]
will be used as theoretical background to understand rea-
sons for (non-)participation. This model is widely used to
explain cancer screening adherence. The HBM states that
health behaviour depends on an individual's desire to
avoid illness and the belief that a specific action will pre-
vent illness. Key factors in explaining health behaviour
are: perceived susceptibility, perceived severity, self-effi-
cacy, perceived benefits, perceived barriers. Reasons for
(non)participation will be measured by eight items scored
on a 4-point scale (e.g. "I think I have a higher chance of
having colorectal cancer than other people my age..."
[totally agree-totally disagree]. These questions are sup-
plemented with 12 questions used in the first screening
round (e.g. "I find that performing the FOBt is disgust-
ing..." [agree – not agree].
Psychological consequences of a positive FOBt
Psychological consequences of screening will be docu-
mented in all invitees at baseline and immediately before
and 2 weeks after undergoing colonoscopy in participants
with a positive FOB test result.
The psychological consequences of receiving a positive
FOB test result will be measured with the validated Dutch
version of the 'Psychological Consequences of screening
Questionnaire' (PCQ)[17]. The English version of this
questionnaire has successfully been used in various
screening studies[18]. The PCQ consists of three sub-
scales: emotion (5 items), physical dysfunction (4 items)
and social dysfunction (3 items). Scores on all items vary
between 0 (not at all) and 3 (often) (e.g. "during the past
week I had problems sleeping..." [not at all – often].
Burden of colonoscopy
The burden of undergoing a colonoscopy will be meas-
ured two weeks after the colonoscopy. Participants will be
asked to rate on a 5-point scale the degree of embarrass-
ment, pain and burden for one of several aspects of the
colonoscopy procedure. Satisfaction with the procedure
will be measured by 20 statements scored on a 4-point
scale (e.g. "the endoscopist treated me with respect..."
[not agree – agree ]. These 20 items-of-concern were devel-
oped from focus group sessions with patients regularly
undergoing colonoscopies.
Ethical approval
Ethical approval was obtained by the Committee on the
Population Screening Act (WBO Committee).
Data analysis
The primary goal of this second FOBt-based screening
round is to assess the overall participation rate and to
compare participation rates between groups (participantsPage 5 of 7
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invitees (3), within all three groups invitees will be rand-
omized to receive a collection paper or not).
Group differences will be calculated using the Chi-square
test. Descriptive statistics will be used to compare baseline
characteristics of the subgroups.
To assess the effect of baseline characteristics and inde-
pendent variables (assessed in the questionnaires) on the
participation rate, multivariate analysis will be performed.
Sample size
In the first round 10.000 persons were invited for screen-
ing. Since we are focussing on the exact same group of per-
sons, the number of persons that will be invited for the
current study will also be 10.000.
Anticipating a 50% participation rate and the invitation of
10.000 eligible persons in the current study, the participa-
tion rate and its 95% confidence interval can be esti-
mated. Assuming a participation rate of around 50%, the
two-sided 95% confidence interval for the participation
rate will extend 1% from the observed proportion, using
the large sample approximation to the binomial distribu-
tion.
This sample size will allow us to detect differences of
approximately 3% in participation rate between sub-
groups, with a continuity corrected chi-square test and a
0.05 two-sided significance level, requesting a power of
80%.
Discussion
This study will provide information on the uptake of a
colorectal cancer screening program using repeated
immunochemical FOBt in the Netherlands. These data are
crucial since reliable and precise data on the degree to
which people are willing to participate in a second round
of screening in the Netherlands are lacking and the effec-
tiveness of a screening program is directly influenced by
the participation rate. Insight into factors that are related
to participation in biannual screening can be used to opti-
mize future screening programs. If this study shows that a
less burdensome faeces collection procedure by the use of
a collection paper has a positive effect on the participation
rate, this information is useful for a future population
screening program. Furthermore, we can anticipate on the
psychological and physical burden of participating in a
screening program based on participant's experiences in
the present study. In a future screening program this bur-
den should be reduced to a minimum to ensure a high
participation rate.
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